Abstract:BACKGROUND:Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory. The mammalian target of rapamycin (mTOR) has been emerged as an important cancer therapeutic target. However, HCC cells often resistant to rapamycin because of the paradoxical activation of Akt by rapamycin. In this study, we investigated whether bortezomib could enhance the antitumor effects of rapamycin.METHODS:The effects of rapamycin and bortezomib on HCC proliferation, apoptosis, migration, and invasiveness in vitro were assessed by CCK-8 analysis, flow cytometry, Hoechst 33342 staining and transwell assays, respectively. Total and phosphorylated protein levels of Akt were detected by Western blotting. The effects of rapamycin and/or bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR. The roles of rapamycin and bortezomib on HCC growth and metastasis in xenograft models were evaluated by tumor volumes and fluorescent signals. The effects of rapamycin and bortezomib on cell proliferation and apoptosis in vivo were test by PCNA and TUNEL staining.RESULTS:Bortezomib synergized with rapamycin to reduce cell growth, induce apoptosis, and inhibit cell mobility in vitro. Further mechanistic studies showed that bortezomib inhibited rapamycin-induced phosphorylated Akt, which in turn enhanced apoptosis of HCC cell lines. The alteration of the mRNA expression of cell cycle inhibitors p53, p27, p21 and apoptosis associated genes Bcl-2, Bax were also involved in the synergistic antitumor effects of rapamycin and bortezomib. P53 inhibitor PFT-α significantly attenuate the effect of rapamycin and bortezomib on cell apoptosis, which indicated that the pro-apoptotic effect of rapamycin and bortezomib may be p53-dependent. Treatment of HCCLM3-R bearing nude mice with rapamycin and bortezomib significantly enhanced tumor growth inhibition (72.4%), comparing with either rapamycin- (54.7%) or bortezomib-treated mice (22.4%). In addition, the lung metastasis was significantly suppressed in mice received the combination treatment (16.6%). The combination treatment of rapamycin and bortezomib significantly inhibited tumor cell proliferation and tumor angiogenesis in vivo.CONCLUSION:The combination of rapamycin with bortezomib could be a novel and promising therapeutic approach to the treatment of HCC.

Rational Combination of SHP2 and Mtor Inhibition for the Treatment of Hepatocellular Carcinoma

Dual Targeting Of Mtorc1/C2 Complexes Enhances Histone Deacetylase Inhibitor-Mediated Antitumor Efficacy In Primary Hcc Cancer In Vitro And In Vivo

Abstract 5363: Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated antitumor efficacy in primary HCC cancerin vitroandin vivo

Vertical Targeting of AKT and Mtor As Well As Dual Targeting of AKT and MEK Signaling is Synergistic in Hepatocellular Carcinoma

Combined Targeting of AKT and Mtor Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model.

Novel Synergistic Antitumor Effects of Rapamycin with Bortezomib on Hepatocellular Carcinoma Cells and Orthotopic Tumor Model

Combined Targeting of AKT and Mtor Synergistically Inhibits Proliferation of Hepatocellular Carcinoma Cells.

Combination of Cetuximab and Rapamycin Enhances the Therapeutic Efficacy in Hepatocellular Carcinoma.

Antitumor Activity of the Combination of an Hsp90 Inhibitor and A Pi3k/Mtor Dual Inhibitor Against Cholangiocarcinoma

Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma

Silmitasertib in Combination With Cabozantinib Impairs Liver Cancer Cell Cycle Progression, Induces Apoptosis, and Delays Tumor Growth in a Preclinical Model

Toripalimab Combined with Anlotinib As the Second-Line Treatment for Advanced Hepatocellular Carcinoma Patients: a Prospective, Single Arm Phase II Clinical Study

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma

Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma

Mammalian target of rapamycin as a novel target in the treatment of hepatocellular carcinoma.

The Anti-Hepatocellular Carcinoma Cell Activity by a Novel Mtor Kinase Inhibitor CZ415

Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma

Synergistic Inhibition of Hepatocellular Carcinoma Growth by Cotargeting Chromatin Modifying Enzymes and Poly (Adp-Ribose) Polymerases

Targeting the Mtor Regulatory Network in Hepatocellular Carcinoma: Are We Making Headway?

Data from Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells